BioSpace News Archive

Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced today that warrants to purchase approximately 5.4 million shares of common stock issued in connection with capital raises in May 2018 and November 2019 with two institutional investors have been exercised at a price of $0.46 pe

Chimeron Bio and George Mason University’s National Center for Biodefense and Infectious Diseases Partner to Develop a Coronavirus (COVID-19) Vaccine using ChaESAR TM Technology Collaboration will test pre-clinical efficacy and safety of vaccine pipeline including COVID-19 and other coronaviruses

UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the first quarter ended March 31, 2020, on Thursday, May 7, 2020 after NASDAQ market close.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, announced that it will hold virtual presentations at the following upcoming investor conferences

Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT), today announced an upcoming oral presentation at this year’s Pediatric Endocrine Society meeting, which will be held virtually. Details of the presentation are as follows: Title: Single Dose Studies of RZ358 in Patients with Congenital Hyperinsulinism: Results of Population PK/PD Modeling and Simulation in Adult and Pediatric Patients Presenter: Brian Roberts, M.D., Rezol

- Exploratory endpoint analyses demonstrated Allocetra’s potential therapeutic effect in resolving cytokine storms in patients with heterogenous pathologies Nes Ziona, Israel, May 28, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that new analyses from its recently completed Phase Ib clinical trial of Allocetra TM in patients with sepsis will be presented as part of an oral presentation at the International Soci

Venture.co Brokerage Services, LLC (“VENTURE.co”) today announces a private capital investment opportunity into HemaFlo Therapeutics, Inc. (“HemaFlo”). VENTURE.co, the Managing Broker-Dealer, will facilitate the $7.5 million ca

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Jefferies 2020 Virtual Healthcare Conference taking place June 2-4, 2020. The Company’s presentation will be on Thursday, June 4, 2020 at 2:30 p.m. ET. Interested parties can access a live webcast of the presentation via a link

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences Company, with proprietary CBD & CBG infused chewing gums and edibles product(s) as well as two ongoing Biotechnology initiatives, today showcased its Final blister pack design for its Black Cur

How Mice That Model Immune Disease’s Cytokine Storms May Point to Solution for Global Pandemic